U.S. Markets open in 5 hrs 19 mins
  • S&P Futures

    4,689.50
    -9.50 (-0.20%)
     
  • Dow Futures

    35,652.00
    -94.00 (-0.26%)
     
  • Nasdaq Futures

    16,376.00
    -16.25 (-0.10%)
     
  • Russell 2000 Futures

    2,260.50
    -9.30 (-0.41%)
     
  • Crude Oil

    72.20
    -0.16 (-0.22%)
     
  • Gold

    1,785.70
    +0.20 (+0.01%)
     
  • Silver

    22.33
    -0.10 (-0.43%)
     
  • EUR/USD

    1.1320
    -0.0024 (-0.2151%)
     
  • 10-Yr Bond

    1.5090
    0.0000 (0.00%)
     
  • Vix

    20.30
    -1.59 (-7.26%)
     
  • GBP/USD

    1.3203
    -0.0004 (-0.0277%)
     
  • USD/JPY

    113.5210
    -0.2160 (-0.1899%)
     
  • BTC-USD

    49,528.55
    -1,027.71 (-2.03%)
     
  • CMC Crypto 200

    1,292.56
    -12.56 (-0.96%)
     
  • FTSE 100

    7,342.54
    +5.49 (+0.07%)
     
  • Nikkei 225

    28,725.47
    -135.15 (-0.47%)
     

Adaptimmune Stock Moves Higher On Cancer Deal With Genentech

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Adaptimmune Therapeutics plc (NASDAQ: ADAP) has announced a collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC: RHHBY), to develop and commercialize allogeneic cell therapies for oncology indications.

  • The collaboration includes developing allogeneic T-cell therapies for up to five shared cancer targets and personalized allogeneic T-cell therapies.

  • Adaptimmune will be responsible for developing candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to produce T-cells (iT cells).

  • Genentech will be responsible for the input TCRs and subsequent clinical development and commercialization.

  • Under the terms of the agreement, Adaptimmune will receive an upfront payment of $150 million and additional payments of $150 million over five years.

  • In addition, Adaptimmune may be eligible to receive research, development, regulatory, and commercial milestones payments potentially exceeding $3 billion in aggregate value.

  • Adaptimmune will also receive tiered royalties on net sales in the mid-single to low-double digits.

  • Adaptimmune has the right to opt-in to a 50/50 U.S. profit/cost share on "off-the-shelf" products.

  • Price Action: ADAP shares are up 27.1% at $6.28 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.